First Light Asset Management LLC Trims Stock Position in Structure Therapeutics Inc. (NASDAQ:GPCR)

First Light Asset Management LLC lowered its stake in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 21.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 398,855 shares of the company’s stock after selling 107,367 shares during the quarter. Structure Therapeutics comprises about 1.0% of First Light Asset Management LLC’s holdings, making the stock its 26th largest position. First Light Asset Management LLC owned 0.70% of Structure Therapeutics worth $10,817,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also modified their holdings of the stock. ANTIPODES PARTNERS Ltd increased its holdings in shares of Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC increased its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC purchased a new position in shares of Structure Therapeutics in the 4th quarter worth about $40,000. Virtus ETF Advisers LLC lifted its stake in shares of Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after purchasing an additional 455 shares in the last quarter. Finally, Assetmark Inc. grew its holdings in shares of Structure Therapeutics by 72.3% during the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock worth $62,000 after purchasing an additional 953 shares during the period. 91.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

GPCR has been the subject of several research reports. William Blair started coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating for the company. Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Tuesday, April 22nd. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $81.29.

Structure Therapeutics Stock Performance

Shares of GPCR opened at $23.74 on Monday. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The stock has a 50-day moving average price of $20.17 and a 200 day moving average price of $27.71. The company has a market capitalization of $1.36 billion, a P/E ratio of -32.08 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. As a group, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.